BriaCell Therapeutics Corp (BCTX)
0.5934
-0.01
(-1.03%)
USD |
NASDAQ |
Nov 14, 16:00
0.6002
+0.01
(+1.15%)
After-Hours: 18:08
BriaCell Therapeutics Enterprise Value: 20.53M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 20.53M |
| November 12, 2024 | 22.35M |
| November 11, 2024 | 23.33M |
| November 08, 2024 | 23.98M |
| November 07, 2024 | 24.48M |
| November 06, 2024 | 24.34M |
| November 05, 2024 | 25.09M |
| November 04, 2024 | 26.70M |
| November 01, 2024 | 27.58M |
| October 31, 2024 | 28.26M |
| October 30, 2024 | 26.69M |
| October 29, 2024 | 28.95M |
| October 28, 2024 | 30.86M |
| October 25, 2024 | 29.91M |
| October 24, 2024 | 30.73M |
| October 23, 2024 | 31.81M |
| October 22, 2024 | 30.09M |
| October 21, 2024 | 27.37M |
| October 18, 2024 | 28.93M |
| October 17, 2024 | 29.12M |
| October 16, 2024 | 28.88M |
| October 15, 2024 | 31.08M |
| October 14, 2024 | 30.91M |
| October 11, 2024 | 34.20M |
| October 10, 2024 | 35.03M |
| Date | Value |
|---|---|
| October 09, 2024 | 31.99M |
| October 08, 2024 | 37.54M |
| October 07, 2024 | 37.18M |
| October 04, 2024 | 34.11M |
| October 03, 2024 | 33.24M |
| October 02, 2024 | 35.03M |
| October 01, 2024 | 23.71M |
| September 30, 2024 | 36.92M |
| September 27, 2024 | 25.90M |
| September 26, 2024 | 20.79M |
| September 25, 2024 | 22.17M |
| September 24, 2024 | 18.26M |
| September 23, 2024 | 19.79M |
| September 20, 2024 | 18.77M |
| September 19, 2024 | 17.33M |
| September 18, 2024 | 14.91M |
| September 17, 2024 | 13.27M |
| September 16, 2024 | 14.00M |
| September 13, 2024 | 16.05M |
| September 12, 2024 | 18.18M |
| September 11, 2024 | 10.60M |
| September 10, 2024 | 10.16M |
| September 09, 2024 | 11.27M |
| September 06, 2024 | 12.16M |
| September 05, 2024 | 11.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.307M
Minimum
May 19 2021
133.84M
Maximum
Apr 08 2022
41.29M
Average
43.54M
Median
Enterprise Value Benchmarks
| CeCors Inc | -- |
| Venus Concept Inc | 43.35M |
| Aurinia Pharmaceuticals Inc | 836.78M |
| Edesa Biotech Inc | 5.103M |
| Lexaria Bioscience Corp | 26.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.214M |
| Total Expenses (Quarterly) | 5.768M |
| EPS Diluted (Quarterly) | -0.07 |
| Earnings Yield | -197.2% |